cas 1075705-01-9|| where to buy 4-Fluoro-2-methoxy-5-nitroaniline

Nombre del producto:4-Fluoro-2-methoxy-5-nitroaniline

IUPAC Name:4-fluoro-2-methoxy-5-nitroaniline

Unidad de embalaje	Stock disponible	Precio($)
CM118763-500g	in stock	ƈĲǪ
CM118763-1000g	in stock	ľŮǪ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1075705-01-9 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1075705-01-9; Fórmula molecular:C7H7FN2O3; Punto de fusión:-; Código de sonrisas:NC1=CC([N+]([O-])=O)=C(F)C=C1OC; Densidad:

: Número de catálogo:CM118763; Peso molecular:186.14; Punto de ebullición:; Nº Mdl:MFCD23098941; Almacenamiento:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Lazertinib; Johnson & Johnson announced new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations. These data showed a comparable response rate in patients treated with SC amivantamab and lazertinib compared to those treated with the intravenous (IV) formulation in the MARIPOSA study, which established the combination of amivantamab and lazertinib as superior to osimertinib. Lazertinib is an oral, third-generation, brain-penetrant EGFR tyrosine kinase inhibitor (TKI) that targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.